Log In
Print
BCIQ
Print
Print this Print this
 

ACY-738

  Manage Alerts
Collapse Summary General Information
Company Acetylon Pharmaceuticals Inc.
DescriptionSelective histone deacetylase 1 (HDAC1) and histone deacetylase 2 (HDAC2) inhibitor
Molecular Target Histone deacetylase 1 (HDAC1) ; Histone deacetylase 2 (HDAC2)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Neurology (unspecified)
Indication DetailsTreat neurodegeneration
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today